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Abstract 
We study the effects of a change in the way patient reimbursements are calculated on the 
prices of pharmaceuticals using quasi-experimental data for Denmark which switched from 
external (where reimbursements are based on prices of similar products in foreign countries) 
to internal reference pricing (where they are based on the cheapest domestic substitute). We 
analyze three therapeutic classes with different treatment durations and show that the reform 
led to substantial price decreases for our lifelong treatment and to less substantial price 
reductions for our medium duration treatment while we do not find significant effects on our 
acute treatment. Moreover, the reform did only affect generics and did not impact original 
products or parallel imports.  
 
JEL classification: I18, C23 
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1 Introduction
The use of reference pricing systems to calculate patients’ reimbursement for prescription
drugs constitutes a worldwide embraced tool to curb medical expenses (Berndt and Dubois
2012; Esp´ın et al. 2011; Lo´pez-Casasnovas and Puig-Junoy 2000). These systems aim at
benefiting patients who prefer cheaper products over more expensive ones, thus targeting
patients’ price sensitivity and inducing competitive pressure on firms.
There exists a large body of empirical evidence that shows that such systems indeed
are e↵ective in curtailing drug prices (Aronsson et al. 2001; Brekke et al. 2007, 2009, 2011;
Danzon and Liu 1998; Kanavos et al. 2008; Pavcnik 2002; Puig-Junoy 2007). Much less
is known, however, about the consequences of the design of such systems on prices. One
particularly important design feature is whether an internal or an external reference price
system is used. Our paper studies the e↵ects of a switch from external reference pricing
to internal reference pricing that was implemented in Denmark in April 2005. Before
the reform, the reference price was calculated as the average price of similar products
in other European countries. After the reform, the reference price is set equal to the
cheapest domestic price of a substitute product. The reform a↵ected all prescription drugs
in Denmark, independent of their patent status.
We empirically study the reform e↵ects using a comprehensive panel set that covers three
therapeutic markets over the time period 2003 to 2006. There are two main mechanisms
through which the reform should drive down prices. First, it should create incentives for
patients to buy the cheapest product within a set of substitutes since they else need to pay
the full price di↵erence out of their own pockets.1 Second, before the reform, prices tended
to cluster at the European average level since the external reference pricing system did not
provide any incentives to set domestic prices below that level.
We speculate that the e↵ects of the reform on prices vary with (i) the duration of
a patients’ medical condition, (ii) the type of the drug producer and (iii) the competitive
situation. Regarding the duration of treatment, we separately consider anticholesterol drugs
that are taken lifelong, antiulcerants that are taken between six weeks and six months and
antibiotics whose treatments only lasts a few days. Our prior is that patients with more
1This argument is formalized by Brekke et al. (2009, 2011)
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chronic conditions are more price sensitive than patients with an acute condition. Apart
from a chronic condition being associated with higher total expenditures, patients in longer
treatments are likely to be more experienced and better informed about their substitution
options and the (perceived) quality of the products. Regarding the type of producer,
we di↵erentiate original producers, generic producers and parallel importers.2 Previous
studies have found that original producers keep their prices high and are able to retain
substantial market shares despite the rise of competition, e.g. after patent expiration. This
behavior has been attributed to heterogeneity in consumer price sensitivity and brand-
loyalty generated by first-mover advantages (Caves et al. 1991; Frank and Salkever 1997;
Grabowski and Vernon 1992). Since our reform targets consumers’ price sensitivity, we
expect that the switch from external to internal reference pricing a↵ects generics prices
more than originals.3 Regarding market competition we, similarly to the seminal work of
Pavcnik (2002) who studies a switch from price cap to external reference pricing in Germany,
allow the reform e↵ects to vary with product market competition. In the limiting case of
a monopoly, the own price constitutes the reference price and producers are hence not
a↵ected by competition or external reference prices. By contrast, if competition within
the set of substitutes is intense, each competitor has incentives to lower prices in order to
secure market shares. We therefore expect the reform e↵ects to be stronger in markets with
more available substitutes.
Apart from Pavcnik (2002), whose findings suggest that producers substantially reduced
prices after the German reform, other relevant work includes Brekke et al. (2009, 2011) as
well as Kaiser et al. (2014). Like Pavcnik (2002), Brekke et al. (2009, 2011) study a switch
from price cap to reference price regulation in Norway, showing that the reform e↵ectively
2Original producers engage in R&D using intellectual property rights to protect their innovations.
Generic firms produce drugs that are bioequivalent copies of original products and may only legally enter
the market after the respective patents have expired. Parallel importers do not engage in manufacturing
and instead buy products in low-price countries, repackage, relabel, and resell them in high-price countries.
Parallel importing is legal within the European Union and in Denmark it is permitted for both on-patent
and o↵-patent pharmaceuticals. Me´ndez (2014) o↵ers a thorough analysis of the market for parallel imports
in Denmark.
3In addition, we expect parallel imports to react more similarly to originals than compared to generics
since a substantially higher share of parallel imported products are originals.
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reduced consumer prices for both original and generic products. In Kaiser et al. (2014), we
conduct a welfare analysis of the Danish change from external to internal reference pricing.
Our previous analysis focuses on anti-cholesterol products only and shows that the reform
e↵ects are stronger for generics than for branded drugs. The present analysis extends our
earlier work by additionally analyzing treatments for semi-chronic and acute conditions.
We find that the switch from external to internal reference pricing primarily a↵ected
generic drugs while prices for parallel imports and originals have remained unchanged. The
negative price e↵ect for generics is larger the longer the treatment lasts — the e↵ects are
both statistically and economically most significant for anti-cholesterols, economically much
smaller for antiulcerants and statistically insignificant for antibiotics. Stronger competition
reinforces the reform e↵ects for anti-cholesterols only while there are no such e↵ects for the
other two treatments.
2 Institutional Background
In Denmark, producers of pharmaceuticals are free to set prices. They must, however,
fortnightly report them to the Danish Medicines Agency (DKMA). DKMA makes them
publicly available online under URL http://medicinpriser.dk which also constitutes the
source of our data. The number and location of pharmacies as well as their markups
are regulated by the government. Danish pharmacists are required to o↵er the cheapest
product, usually a generic, among available substitutes but patients may opt for a more
expensive substitute. In that case, they have to pay the price di↵erence out of their
own pockets. The level of patients’ copayments is calculated on the basis of a patient’s
own annual expenditures and the reference price. In particular, a patient’s co-payment
pc is the di↵erence between the pharmacy retail price (list price, pl) and the product of
the reimbursement rate ⇢ and the reference price, pc = pl   ⇢pr. Consumers in chronic
treatments get as much as 80 percent of their expenses reimbursed, while patients with an
acute condition obtain only around 40 percent refund.
The reference price reform took e↵ect on April 1, 2005. Before the reform, the reference
price for a given product was defined as the pharmacy retail price of the chosen product up
to the average price of the same product in the EU-15 member states, excluding Greece,
5
Luxembourg, Spain, and Portugal. Once the retail price exceeded the EU average price, the
reference price was set equal to the EU average price. After the reform, the reference price
was set to be equal to the cheapest domestic price among available substitutes. Substitu-
tion groups are defined by the Danish Medicines Agency on the basis of active substance,
administration form, strength and package size.
Our analysis focuses on a base period during which no information about prospective
changes in the regulatory system was available. This period lasted from September 15,
2003 to June 7, 2004. Our treatment period covers the time span between April 1, 2005,
when the reform took e↵ect, and September 25, 2006, when a new regulatory measure was
introduced.
3 Data
Our data set contains fortnightly prices and other characteristics of pharmaceutical prod-
ucts in three therapeutical markets: 228 anti-cholesterols, 251 antiulcerants, and 152 an-
tibiotics that we observe for 59 fortnightly time periods. This amounts to a total of 21,895
observations on 631 unique products. We normalize prices using the World Health Orga-
nization defined daily dosages (DDD) to make products of di↵erent strengths and package
sizes comparable.
The Appendix displays descriptive statistics of our variables. The table shows that
one DDD of antibiotics costs on average more than one DDD of statins or antiulcerants.
Average reference prices are higher than average pharmacy purchase prices since the latter
do not include prescription fees or taxes. The average number of products and the average
number of producers is relatively stable between the two time periods. The average number
of substitution groups and the average number of products in a substitution group di↵ers
substantially across markets with antibiotics having around 80 di↵erent substitution groups
with around two products each and anti-cholesterols less than 40 substitution groups and
each with around six products. Antiulcerants constitute an intermediate case. The table
also shows that the share of generics in the chronic and semi-chronic conditions is higher
than the share of original products. Parallel imports are also well represented in these
groups. This is di↵erent for antibiotics where originals dominate.
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4 Empirical Approach
Our dependent variable pharmacy purchase price in DDD is skewed and non-negative
which implies that log-linear regression is not advisable as it leads to inconsistent estimates
in the presence of heteroskedasticity (Manning and Mullahy 2001). We therefore follow
a suggestion by Santos Silva and Tenreyro (2006) and use a Poisson pseudo-maximum-
likelihood estimator instead. The coe cients in this model are semi-elasticities which
makes them directly interpretable. Following Pavcnik (2002), our regression equation takes
the following form:
exp(pfjt) = ⇢Rt + ↵1Rt ⇤ dopjt + ↵2Rt ⇤ dpijt +  1zjt +  2Rt ⇤ zjt +Xjt + µj + ✏jt, (1)
where Rt denotes a dummy variable that is coded one in the treatment period and zero
otherwise. The terms dop and dpi constitute dummy variables that indicate if the product is
an original (“op”) or if it is a parallel import (“pi”) respectively. We interact these dummy
variables with the reform dummy to allow for di↵erent reform e↵ects for di↵erent types of
producers. The variable zjt denotes the number of products in a substitution group that
measures the current competitive situation of product j at time t. We interact zjt with the
reform dummy to allow competition for having di↵erent e↵ects on prices before and after
the reform. The term µj lumps together all product-specific time-invariant characteristics of
product j like strength, active ingredient, package size and substitution group. We hence do
not need to separately account for them. The variables included in vectorXjt are a dummy
indicating if the product belongs to the prescription (combination of strength and package
size) with highest sales in period t and a set of time dummies. The “common dosage”
dummy constitutes another measure of a product’s competitive situation and captures
learning by physicians and patients as new drugs become available or as older drugs’ patents
expire. The term ✏jt is an iid normal distributed error term.
5 Results
Table 1 displays our estimation results. Our most parsimonious model, shown in columns
(1) includes a dummy variable for the reform only. The associated coe cient is to be
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interpreted as a 46 percent decrease in prices for anti-cholesterols. There are no statistically
significant e↵ects for antiulcerants and antibiotics. The other specifications, displayed in
columns (2) to (5), additionally include a set of time and product name dummies. Including
these almost halves the reform e↵ect on anti-cholesterols and leaves the results for the two
other drug types una↵ected as shown in columns (2).
In columns (3), we allow the reform e↵ects to di↵er between di↵erent types of drug
producers. The reform dummy is now to be interpreted as the e↵ect of the reform on
generics, while the sum of the coe cient on the reform dummy and the coe cients on
the interactions reform ⇥ OP and reform ⇥ P constitutes the reform e↵ect on originals
and parallel imports, respectively. The coe cients on the interaction variables alone are
to be interpreted as the percentage deviation from the reform e↵ect on generics. Column
(3) in Table 1 shows that the reform induced a price reduction of generic anti-cholesterols
by 61 percent. The e↵ect on parallel imports is -27.1 percent (-61 percent+33.9 percent)
and statistically weakly significant as shown on the bottom of the table. By contrast, the
e↵ect is statistically insignificant for original products. While we neither find statistically
significant e↵ects on generic or original antiulcerants, we do find statistically significant
negative e↵ects on parallel imports. Our results for antibiotics are qualitatively similar to
the ones for anti-cholesterols but economically substantially smaller. The reform e↵ect on
generics is estimated to be -4.6 percent and is weakly significant. For parallel imports, it is
-29.7 percent. The latter result is to be interpreted with caution since there are only two
parallel imported drugs in the antibiotics market.
Specification (4) additionally controls for the number of substitutes a product is facing
competition from as well as its interaction with the reform dummy. The coe cient on the
interaction term is statistically significantly negative for anti-cholesterols only while it is
statistically insignificant for the other two treatments. This may indicate that consumers
are better aware of their substitution possibilities in life-long treatments compared to treat-
ments of shorter duration which makes them more willing to switch to cheaper substitutes
once the reference pricing system changes. The e↵ect of the number of substitutes before
the reform is negative and statistically significant for antiulcerants and antibiotics, but not
for anti-cholesterols. We attribute the latter e↵ect to the importance of brand loyalty in
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this market.4 Controlling for competition reduces the coe cient on the reform dummy
variable for anti-cholesterol generics to -33.2. The reform e↵ect rises with the number of
competitors; it is -52.7 percent for the average number of competitors in a substitution
group. Controlling for competition makes the reform e↵ect on parallel imported drugs
statistically insignificant. Similarly, the e↵ect on parallel imported antiulcerants becomes
statistically insignificant while the results now show that it entailed statistically weakly
significant price reductions of 3.2 percent for generic antiulcerants. Our estimation results
for antibiotics are qualitatively and quantitatively similar to the ones that did not control
for competition.
Finally, columns (5) additionally include common dosages. This additional control
variable does not a↵ect any of the results we already discussed and is statistically significant
and negative only for statins and antiulcerants.
6 Conclusion
While reference price systems constitute widely embraced cost containment tools, little is
known about their design. Using data on a reference price reform in Denmark, we study
how e↵ective internal reference pricing is compared to external reference pricing in bringing
down prices for prescription drugs. Our analysis also studies what di↵erence it makes (i)
how long a medical treatment with a particular drug lasts, (ii) if the drugs is a generic,
a parallel import or an original and (iii) what role competition plays. We show that the
switch from external to internal reference pricing lead to substantial price reduction for
anti-cholesterol generics and much less substantial reductions for antiulcerants generics.
By contrast, prices of original products and, by and large, parallel imports, have remained
unchanged. In addition, we only find statistically significant and economically substantial
e↵ects for longer treatments while the reform did not a↵ect prices for antibiotics. Finally,
competition statistically and economically moderates the reform e↵ects for anti-cholesterols
only while it does not have a statistically significant additional e↵ect on the two treatments
4Running the same specification for anti-cholesterols leaving out the name dummies results in a negative
and significant sign which corresponds well with the “generic competition paradox” (Grabowski and Vernon,
1992) where original producers increase prices when faced by more intense competition.
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of shorter duration.
Overall, our findings suggest that internal reference pricing is likely to only drive down
prices of drugs for treatments of long duration. They also underscore how important it
is that consumers are well informed about their substitution options for any competition-
enforcing reform to have any statistically and economically significant e↵ect.
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Appendix: descriptive statistics
Type of treatment Variable
Before reform After reform
Mean Std. Dev. Mean Std. Dev.
Anti-cholesterol
Pharmacy purchase price pf 6.18 4.48 3.90 4.33
Reference price pr 7.38 5.51 4.35 5.36
Number of products 125.72 4.50 123.00 12.97
Number of firms 19.00 0.46 21.89 2.36
Number of substitution groups 39.90 0.64 38.95 0.98
Products in substitution group 6.94 4.56 5.01 2.57
Original product (=1 if original) 0.30 0.46 0.28 0.45
Generic product (=1 if generic) 0.43 0.50 0.56 0.50
Parallel import (=1 if pi) 0.27 0.45 0.16 0.37
Total Observations 2,511 4,617
Antiulcerants
Pharmacy purchase price pf 6.70 7.01 6.43 6.84
Reference price pr 10.37 11.56 9.43 10.71
Number of products 130.35 2.43 145.55 15.50
Number of firms 22.65 0.49 21.33 0.93
Number of substitution groups 69.30 1.81 60.59 1.25
Products in substitution group 3.01 2.10 3.58 1.96
Original product (=1 if original) 0.32 0.47 0.18 0.39
Generic product (=1 if generic) 0.55 0.50 0.59 0.49
Parallel import (=1 if pi) 0.13 0.34 0.23 0.42
Total Observations 2,606 5,610
Antibiotics
Pharmacy purchase price pf 7.54 9.81 7.53 16.74
Reference price pr 13.95 17.99 13.45 24.48
Number of products 124.45 2.55 104.29 3.50
Number of firms 11.75 0.79 10.87 0.61
Number of substitution groups 84.05 1.61 76.64 2.19
Products in substitution group 2.00 1.24 1.68 0.86
Original product (=1 if original) 0.61 0.49 0.59 0.49
Generic product (=1 if generic) 0.38 0.48 0.39 0.49
Parallel import (=1 if pi) 0.02 0.13 0.02 0.14
Total Observations 2,488 4,759
Notes: The Appendix reports summary statistics for all variables in each therapeutic group. Prices
are fortnightly averages for a defined daily dose in Danish krones. All figures deflated using consumer
prices index with June 2005 as basis. Exchange rates in June 2005: DKK 1 = $ 0.1634 = e 0.1343.
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